Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
582 SEK | +8.08% | +3.03% | +7.34% |
05-23 | Camurus' Rare Growth Disorder Drug Accepted for Review in EU | MT |
05-23 | Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.34% | 2.93B | |
+39.82% | 734B | |
+32.76% | 591B | |
-7.31% | 350B | |
+14.23% | 315B | |
+0.86% | 276B | |
+14.02% | 238B | |
+8.83% | 206B | |
-6.26% | 204B | |
+4.51% | 161B |
- Stock Market
- Equities
- CAMX Stock
- News Camurus AB
- Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024